Serpin B5 is a CEA-interacting biomarker for colorectal cancer

International Journal of Cancer

Volumn 134, Issue 7, 2014, Pages 1595-1604

  Baek, Ji Yeon ^a   Yeo, Hyun Yang ^a   Chang, Hee Jin ^a   Kim, Kyung Hee ^a   Kim, Sun Young ^a   Park, Ji Won ^a   Park, Sung Chan ^a   Choi, Hyo Seong ^a   Kim, Dae Yong ^a   Oh, Jae Hwan ^a  

^a National Cancer Center   (South Korea)

Author keywords

carcinoembryonic antigen (CEA); colorectal cancer; maspin; prognostic factor; Serpin B5

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MASPIN; TUMOR MARKER;

AMINO ACID SEQUENCE; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL INFILTRATION; CELL LEVEL; COLORECTAL CANCER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LYMPH NODE METASTASIS; LYMPHATIC INVASION; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PERINEURAL INVASION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TUMOR INVASION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

CARCINOEMBRYONIC ANTIGEN (CEA); COLORECTAL CANCER; MASPIN; PROGNOSTIC FACTOR; SERPIN B5;

CACO-2 CELLS; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DOWN-REGULATION; HCT116 CELLS; HUMANS; LYMPHATIC METASTASIS; PROGNOSIS; SERPINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84892582589     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28494     Document Type: Article

References (37)

1. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010; 116: 544-73.
2. Moghimi-Dehkordi B, Safaee A,. An overview of colorectal cancer survival rates and prognosis in Asia. World J Gastrointest Oncol 2012; 4: 71-5.
3. Bacolod MD, Barany F,. Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. Ann Surg Oncol 2011; 18: 3694-700.
4. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-27.
5. Khalkhali-Ellis Z,. Maspin: the new frontier. Clin Cancer Res 2006; 12: 7279-83.
6. Pemberton PA, Tipton AR, Pavloff N, et al. Maspin is an intracellular serpin that partitions into secretory vesicles and is present at the cell surface. J Histochem Cytochem 1997; 45: 1697-706.
7. Futscher BW, Oshiro MM, Wozniak RJ, et al. Role for DNA methylation in the control of cell type specific maspin expression. Nat Genet 2002; 31: 175-9.
8. Reis-Filho JS, Milanezi F, Schmitt FC,. Maspin is expressed in the nuclei of breast myoepithelial cells. J Pathol 2002; 197: 272-3; author reply 273-4.
9. Sheng S,. A role of novel serpin maspin in tumor progression: the divergence revealed through efforts to converge. J Cell Physiol 2006; 209: 631-5.
10. Bodenstine TM, Seftor RE, Khalkhali-Ellis Z, et al. Maspin: molecular mechanisms and therapeutic implications. Cancer Metastasis Rev 2012; 31: 529-51.
11. Zou Z, Anisowicz A, Hendrix MJ, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994; 263: 526-9.
12. Shao LJ, Shi HY, Ayala G, et al. Haploinsufficiency of the maspin tumor suppressor gene leads to hyperplastic lesions in prostate. Cancer Res 2008; 68: 5143-51.
13. Umekita Y, Yoshida H,. Expression of maspin is up-regulated during the progression of mammary ductal carcinoma. Histopathology 2003; 42: 541-5.
14. Cao D, Zhang Q, Wu LS, et al. Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases. Mod Pathol 2007; 20: 570-8.
15. Song SY, Son HJ, Kim MH, et al. Prognostic significance of maspin expression in human gastric adenocarcinoma. Hepatogastroenterology 2007; 54: 973-6.
16. Bettstetter M, Woenckhaus M, Wild PJ, et al. Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer. J Pathol 2005; 205: 606-14.
17. Goulet B, Chan G, Chambers AF, et al. An emerging role for the nuclear localization of maspin in the suppression of tumor progression and metastases. Biochem Cell Biol 2012; 90: 22-38.
18. Zheng H, Tsuneyama K, Cheng C, et al. Maspin expression was involved in colorectal adenoma-adenocarcinoma sequence and liver metastasis of tumors. Anticancer Res 2007; 27: 259-65.
19. Märkl B, Arnholdt HM, Jähnig H, et al. Shift from cytoplasmic to nuclear maspin expression correlates with shorter overall survival in node-negative colorectal cancer. Hum Pathol 2010; 41: 1024-33.
20. Dietmaier W, Bettstetter M, Wild PJ, et al. Nuclear Maspin expression is associated with response to adjuvant 5-fluorouracil based chemotherapy in patients with stage III colon cancer. Int J Cancer 2006; 118: 2247-54.
21. Ngamkitidechakul C, Warejcka DJ, Burke JM, et al. Sufficiency of the reactive site loop of maspin for induction of cell-matrix adhesion and inhibition of cell invasion. Conversion of ovalbumin to a maspin-like molecule. J Biol Chem 2003; 278: 31796-806.
22. Yin S, Li X, Meng Y, et al. Tumor-suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase. J Biol Chem 2005; 280: 34985-96.
23. Bailey CM, Khalkhali-Ellis Z, Kondo S Marqaryan NV, et al. Mammary serine protease inhibitor (Maspin) binds directly to interferon regulatory factor 6: identification of a novel serpin partnership. J Biol Chem 2005; 280: 34210-7.
24. Hammarström S,. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999; 9: 67-81.
25. Kuespert K, Pils S, Hauck CR,. CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol 2006; 18: 565-71.
26. Park JG, Oie HK, Sugarbaker PH, et al. Characteristics of cell lines established from human colorectal carcinoma. Cancer Res 1987; 47: 6710-8.
27. Oh JH, Ku JL, Yoon KA, et al. Establishment and characterization of 12 human colorectal-carcinoma cell lines. Int J Cancer 1999; 81: 902-10.
28. Trainer DL, Kline T, McCabe FL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int J Cancer 1988; 41: 287-96.
29. Yoo BC, Ku JL, Hong SH, et al. Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines. Int J Cancer 2004; 108: 532-9.
30. Shin YK, Yoo BC, Chang HJ, et al. Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 2005; 65: 3162-70.
31. Punt CJ, Buyse M, Kohne CH, et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 2007; 99: 998-1003.
32. Romani AA, Soliani P, Desenzani S, et al. The associated expression of Maspin and Bax proteins as a potential prognostic factor in intrahepatic cholangiocarcinoma. BMC Cancer 2006; 6: 255.
33. Cho JH, Kim HS, Park CS, et al. Maspin expression in early oral tongue cancer and its relation to expression of mutant-type p53 and vascular endothelial growth factor (VEGF). Oral Oncol 2007; 43: 272-7.
34. Shi ZR, Tsao D, Kim YS,. Subcellular distribution, synthesis, and release of carcinoembryonic antigen in cultured human colon adenocarcinoma cell lines. Cancer Res 1983; 43: 4045-9.
35. Song SY, Lee SK, Kim DH, et al. Expression of maspin in colon cancers: its relationship with p53 expression and microvessel density. Dig Dis Sci 2002; 47: 1831-5.
36. Fung CL, Chan C, Jankova L, et al. Clinicopathological correlates and prognostic significance of maspin expression in 450 patients after potentially curative resection of node-positive colonic cancer. Histopathology 2010; 56: 319-30.
37. Boltze C,. Loss of maspin is a helpful prognosticator in colorectal cancer: a tissue microarray analysis. Pathol Res Pract 2005; 200: 783-90.